Compare Honeywell International Inc (HON) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs Illumina, Inc. — how do they compare? Honeywell International Inc trades at $206.49 (market cap $65.48B), while Illumina, Inc. trades at $268.5 (market cap $39.95B). The key difference: Honeywell International Inc is the larger of the two by market cap, and Honeywell International Inc pays a 1.36% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Honeywell International Inc for 90 Days and Illumina, Inc. for 83 Days on average.
| HON | ILMN | |
|---|---|---|
Market Cap | $65.48B | $39.95B |
Volume | 2,047,782 | 3,169,503 |
Sector | Industrials | Health |
52-Week High | $248.79 | $293.69 |
52-Week Low | $188.14 | $91.00 |
Typical Hold Time | 90 Days | 83 Days |
Enterprise Value | $90.27B | $41.31B |
Dividend Yield | 1.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $208.11, down 2.24% on the day, with a bearish technical signal from moving averages but strong fundamentals including a low P/E of 7.94 and robust ROE of 47.43%. Recent earnings beats and a $300 million refinery project win highlight operational strength, while the company's post-spin focus on automation drives growth expectations.
The outlook is positive with a consensus price target of $259.25 implying 24.6% upside, supported by analyst bullishness (66.7% buy ratings). Risks include rising debt-to-asset ratios and cyclical exposure, but solid cash flow and dividend payments provide stability amid near-term volatility.
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
